/ Print /

Pharmacies

Five ways to combat growing polypharmacy among childrenOne expert believes managed care executives are key to a necessary paradigm shift in pediatric polypharmacy.
Opinion: Top 2 takeaways from UBS Global Healthcare ConferenceThe conference raised important points about unregulated growth opportunities and new pharmacy arena players.
Pharmaceutical pipeline: Top 4 conditions to watch
Pharmaceutical pipeline: Top 4 conditions to watchAlthough drug spend is increasing for inflammatory conditions, diabetes, and oncology, there are some promising developments in the pipeline.
Top four approaches to reduce pharmaceutical costs
Top four approaches to reduce pharmaceutical costsMCOs are fighting back against rising pharmaceutical costs. Here are the top strategies they are embracing.
Four health systems develop opioid mitigation programsAlternatives to opioids programs emerge as viable tools to mitigate the crisis.
Three ways technology is improving pharmacyTechnology advances in pharmacy include innovations that improve medication safety, efficiency, and patient compliance.
Value-based drug contracting shifts risk to manufacturersValue-based drug contracting between manufacturers and payers is picking up steam—appropriate timing as the healthcare industry moves toward value-based payment and purchasing and away from fee-for-service.
Opinion: Top 2 takeaways from Asembia Specialty Pharmacy SummitThe conference raised important points about value-based contracts and the specialty pharmacy space.
Patients who need PCSK9 inhibitors cant get themStudy: PCSK9 inhibitors are being rejected by insurers at very high rates even in high-risk patients like those with familial hypercholesterolemia.
Incremental clinical advances for Duchenne Muscular DystrophyJust last year, the FDA approved Exondys 51 (eteplirsen) for DMD, over the recommendations of FDA scientists and an external scientific advisory committee. Read more.